AMPH — Amphastar Pharmaceuticals, Inc.

Summary of Amphastar Pharmaceuticals Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Revenues: $171.2 million, a slight increase from $170.5 million year-over-year.
• BAQSIMI Revenue: Decreased 15% to $32.4 million due to lower average selling prices, despite an 8% increase in unit sales.
• Primatene MIST Revenue: Grew 2% to $29.8 million, driven by strong consumer demand and marketing efforts.
• Gross Margin: Declined to 71% from 50% year-over-year, impacted by lower selling prices and increased costs.
• Net Income: Decreased to $6.4 million ($0.14 per share) from $25.3 million ($0.51 per share) in Q1 2025.
• Adjusted Net Income: Decreased to $19.5 million ($0.42 per share) from $36.9 million ($0.74 per share).
• Cash Flow from Operations: Approximately $47.8 million, with $29.5 million used for share repurchases.

2. Strategic Updates and Business Highlights

• Product Portfolio: Continued focus on expanding branded and differentiated products, with BAQSIMI and Primatene MIST as key growth drivers.
• New Launches: Successfully launched AMP-007 (Ipratropium Bromide inhalation product), the first generic of its kind, expected to provide significant near-term revenue.
• Pipeline Development: Advancing complex and proprietary products, including biosimilars and oncology/immunology assets, with planned launches in 2027.

3. Forward Guidance and Outlook

• BAQSIMI Revenue Growth: Now expected to be flat to low single-digit growth due to pricing pressures, with a 3% list price increase effective May 1.
• Overall Sales Guidance: Maintained mid-single-digit to high single-digit growth outlook for 2026, supported by the new Ipratropium product and stable performance in other areas.
• Long-term Strategy: Focus on diversifying the portfolio and investing in proprietary pipeline assets to ensure sustained growth.

4. Bad News, Challenges, or Points of Concern

• Pricing Pressures: Significant impact on BAQSIMI revenue due to increased rebates and competitive pricing dynamics, particularly in the 340B pharmacy program.
• Declining Gross Margins: Lower margins attributed to decreased sales of higher-margin products and increased operational costs.
• Glucagon Sales Decline: A 56% drop in glucagon injection sales due to competition and market shifts, with expectations of continued decline, albeit at a slower rate.

5. Notable Q&A Insights

• BAQSIMI Pricing Strategy: Management is addressing pricing issues through third-party validation of rebates and expects improvements in pricing dynamics moving forward.
• International Market Strategy: Plans to discontinue sales in select international markets, but overall impact on revenue is expected to be minimal as U.S. sales dominate.
• Pipeline Updates: No current regulatory alignment with the FDA for the synthetic corticotropin product, but potential for expedited approval exists. Insulin aspart remains on track for commercialization in 2027.
• Primatene MIST Competition: Management believes generic competition will be challenging due to the product's established brand presence and regulatory hurdles.

Overall, Amphastar's Q1 2026 results reflect a mixed performance with growth in certain areas but significant challenges in pricing and competition impacting key products. The company remains focused on strategic investments and navigating a dynamic market environment.